Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome

• Published in: Sleep (New York, N.Y.) N.Y.), 2004-08, Vol.27 (5), p.907-914
• Main Authors: ALLEN, Richard, BECKER, Philip M, BOGAN, Richard, SCHMIDT, Markus, KUSHIDA, Clete A, FRY, June M, POCETA, J. Steven, WINSLOW, David
• Format: Article
• Language: English
• Subjects: Antiparkinson Agents - pharmacology; Antiparkinson Agents - therapeutic use; Behavioral psychophysiology; Biological and medical sciences; Disorders of higher nervous function. Focal brain diseases. Central vestibular syndrome and deafness. Brain stem syndromes; Dopamine Agonists - pharmacology; Dopamine Agonists - therapeutic use; Double-Blind Method; Female; Fundamental and applied biological sciences. Psychology; Humans; Indoles - pharmacology; Indoles - therapeutic use; Male; Medical sciences; Middle Aged; Nervous system (semeiology, syndromes); Neurology; Neurotransmission and behavior; Nocturnal Myoclonus Syndrome - drug therapy; Polysomnography - instrumentation; Psychology. Psychoanalysis. Psychiatry; Psychology. Psychophysiology; Restless Legs Syndrome - drug therapy; Sleep, REM - drug effects
• ISSN: 0161-8105; 1550-9109
• DOI: 10.1093/sleep/27.5.907

Polysomnographic study evaluating the efficacy of ropinirole for the treatment of patients with restless legs syndrome (RLS) suffering from periodic leg movements in sleep (PLMS). Double-blinded, placebo-controlled, parallel-group study. 15 tertiary referral centers in the USA. 65 patients with RLS and PLMS. Ropinirole (0.25-4.0 mg per day) or placebo for 12 weeks. Data from 59 patients were included in the primary endpoint analysis. PLMS per hour decreased more with ropinirole (48.5 to 11.8), compared with placebo (35.7 to 34.2; adjusted treatment difference: -27.2; 95% confidence interval [CI]: -39.1, -15.4; P < .0001). Periodic limb movements with arousal per hour decreased from 7.0 to 2.5 with ropinirole but increased from 4.2 to 6.0 with placebo (adjusted treatment difference: -4.3, 95% CI: -7.6, -1.1; P = .0096). Periodic limb movements while awake per hour decreased from 56.5 to 23.6 with ropinirole but increased from 46.6 to 56.1 with placebo (adjusted treatment difference: -39.5; 95% CI: -56.9, -22.1; P < .0001). Ropinirole treatment significantly improved patients' ability to initiate sleep (P < .05) and the amount of Stage 2 sleep compared with placebo (P < .001). There were also non-significant trends toward increases in total sleep time and sleep efficiency. Sleep adequacy (measured on the subjective Medical Outcomes Study sleep scale) was significantly improved with ropinirole treatment (adjusted treatment difference: 12.1; 95% CI: 1.1, 23.1; P = .0316). In contrast, the placebo group showed a greater increase in Stage 3/4 sleep (P < .01). No serious adverse events occurred in either group. Ropinirole is effective in the treatment of both the sleep and waking symptoms of RLS.